Capstone Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Capstone Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$560K	Sell	1,908 -202	-10%	-$58.4K	0.02%	844
2017 Q1	$743K	Sell	2,110 -308	-13%	-$69.2K	0.02%	693
2016 Q4	$445K	Sell	2,418 -791	-25%	-$161K	0.01%	1019
2016 Q3	$827K	Sell	3,209 -36	-1%	-$9.27K	0.02%	666
2016 Q2	$693K	Buy	3,245 +282	+10%	+$63K	0.02%	736
2016 Q1	$611K	Sell	2,963 -138	-4%	-$26.5K	0.02%	793
2015 Q4	$784K	Sell	3,101 -238	-7%	-$48.9K	0.02%	682
2015 Q3	$549K	Buy	+3,339	New	+$591K	0.02%	849
2013 Q4	–	Sell	-874	Closed	-$137K	–	1935
2013 Q3	$137K	Sell	874 -6	-0.7%	-$1.11K	﹤0.01%	1917
2013 Q2	$152K	Buy	+880	New	+$135K	﹤0.01%	1843

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capstone Asset Management's NKTR Position: Q2 2017 in Review

Capstone Asset Management reduced its Nektar Therapeutics (NKTR) stake by 9.6% in Q2 2017, selling an estimated $58.4K and leaving 1,908 shares worth $560K. The position accounts for 0.02% of the portfolio, ranked #844.

Capstone Asset Management first reported a position in NKTR in Q2 2013 and has held it in 10 quarters since. The position peaked at $827K in Q3 2016. 197 funds tracked by Wall St. Rank hold NKTR as of Q2 2017.

Capstone Asset Management held 1,908 shares of Nektar Therapeutics worth $560K as of Q2 2017.
Capstone Asset Management sold 202 Nektar Therapeutics shares in Q2 2017, an estimated $58.4K.
Nektar Therapeutics made up 0.02% of Capstone Asset Management's portfolio in Q2 2017, its #844 holding.
Capstone Asset Management first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 10 quarters since.
Capstone Asset Management's Nektar Therapeutics position peaked at $827K in Q3 2016.
197 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.